Report #2824546

Received Feb 4, 2025

A note on interpretation. VAERS reports are unverified and may be incomplete or coincidental. A report does not establish that a vaccine caused an event, and counts should not be used to calculate incidence or infer causation. Full disclaimer

Overview

Sex: Female
Age: Age unknown
State: FL
Recovered: Unknown
Vaccinated: Jan 21, 2025
Onset: Jan 21, 2025
Days to onset: 0
Hospital days: —

Vaccines (1)

Type	Name	Manufacturer	Dose	Lot	Route / Site
RSV	RSV (AREXVY)	GLAXOSMITHKLINE BIOLOGICALS	2	255T2	—

Symptoms (1)

Extra dose administered

Symptom narrative

a second dose was administered; This non-serious case was reported by a pharmacist via call center representative and described the occurrence of extra dose administered in a 84-year-old female patient who received RSVPreF3 adjuvanted (Arexvy) (batch number 255T2, expiry date 05-DEC-2025) for prophylaxis. Previously administered products included Arexvy (received 1st dose a year ago). On 21-JAN-2025, the patient received the 2nd dose of Arexvy. On 21-JAN-2025, an unknown time after receiving Arexvy, the patient experienced extra dose administered (Verbatim: a second dose was administered). The outcome of the extra dose administered was unknown. Additional Information: GSK Receipt Date: 22-JAN-2025 The pharmacist reported that a patient received a first dose of Arexvy last year and a second dose was administered which led to extra dose administered. The pharmacist asked for potential adverse effects.